Integer is a medical-device contract development and manufacturing organization serving cardio and vascular, neuromodulation, and cardiac rhythm management markets; its immediate business story is now dominated by KKR’s announced take-private transaction rather than a new operating initiative.
The deal clears one regulatory hurdle, but the economics do not change. Early termination of the HSR waiting period satisfies one closing condition. 〔0〕 The consideration remains $127 per share in cash, representing approximately $5.7 billion of enterprise value.
This is progress, not a surprise reset. HSR clearance was a customary and anticipated step in the previously announced merger, so the filing reduces execution uncertainty modestly without changing the offer price, strategic rationale, or expected closing window. Other antitrust and foreign-investment approvals, along with stockholder approval, remain outstanding. 〔1〕
The next gating event is now clearly scheduled. Integer’s virtual special meeting is set for October 21, 2026, and the board continues to recommend that stockholders vote for the merger. 〔2〕
Bottom line: The filing confirms the KKR transaction is advancing normally, but it does not materially change the standing deal story. The shareholder vote and remaining regulatory approvals are still the meaningful execution steps.
Read the original 8-K on SEC EDGAR ↗